Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.58 |
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | NPC1 | O15118 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 3/20 | 0.48 |
| ▸ | ILK | Q13418 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31733941 | 0.86 | RAB9A (0.59) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL5708098 | 0.86 | KDM4E (0.62) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL11676970 | 0.83 | KDM4E (0.58) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL231307 | 0.82 | KDM4E (0.75) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL28590372 | 0.80 | KDM4E (0.58) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL23723 | 0.80 | KDM4E (0.58) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL12854008 | 0.80 | KDM4E (0.72) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL3355189 | 0.80 | KDM4E (0.54) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL3355183 | 0.80 | KDM4E (0.54) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL5545830 | 0.77 | KDM4E (0.64) | KDM4ERAB9ANPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103214428-B | Benzothiazole-cyanophenyl compound serving as hydrazine fluorescence probe as well as preparation method and application method of benzothiazole-cyanophenyl compound | UNIV ZHEJIANG | 2014-11-26 | — | — | CN | claimed |
| CN-103214428-A | Benzothiazole-cyanophenyl compound serving as hydrazine fluorescence probe as well as preparation method and application method of benzothiazole-cyanophenyl compound | UNIV ZHEJIANG | 2013-07-24 | — | — | CN | claimed |
| CN-103214428-B | Benzothiazole-cyanophenyl compound serving as hydrazine fluorescence probe as well as preparation method and application method of benzothiazole-cyanophenyl compound | UNIV ZHEJIANG | 2014-11-26 | — | — | CN | disclosed |
| CN-103214428-A | Benzothiazole-cyanophenyl compound serving as hydrazine fluorescence probe as well as preparation method and application method of benzothiazole-cyanophenyl compound | UNIV ZHEJIANG | 2013-07-24 | — | — | CN | disclosed |
| EP-2159216-B1 | 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS | ORGANON NV (NL) | 2011-10-12 | — | — | EP | disclosed |
| EP-2159216-A1 | Ih - Modulators | N.V. Organon (NL) | 2010-03-03 | — | — | EP | disclosed |
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| CN-1275909-A | In-modulators | AKZO NOBEL NV (NL) | 2000-12-06 | — | — | CN | disclosed |
| EP-1035843-A2 | I h?-MODULATORS | Akzo Nobel N.V. (NL) | 2000-09-20 | — | — | EP | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| WO-1999018941-A2 | Ih-MODULATORS | AKZO NOBEL N.V. (NL) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | KDM4E 1272/4885RAB9A 2259/4885NPC1 536/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | KDM4E 1272/4885RAB9A 2259/4885NPC1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.